Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESRRG | P62508 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786149 | 0.79 | HRH3 (0.63) | HRH3 | |
| SCHEMBL2785130 | 0.77 | DRD2 (0.39) | HRH3DRD2DRD1DRD3DRD5 | |
| SCHEMBL29175059 | 0.72 | DRD2 (0.68) | HRH3DRD2DRD1DRD3DRD5 | |
| SCHEMBL30628624 | 0.72 | DRD2 (0.68) | HRH3DRD2DRD1DRD3DRD5 | |
| SCHEMBL2786314 | 0.70 | HRH3 (0.53) | HRH3 | |
| SCHEMBL2785064 | 0.67 | HRH3 (1.00) | HRH3 | |
| SCHEMBL2784785 | 0.66 | HRH3 (1.00) | HRH3 | |
| SCHEMBL2786737 | 0.66 | HRH3 (1.00) | HRH3 | |
| SCHEMBL7597675 | 0.66 | HRH3 (0.98) | HRH3 | |
| SCHEMBL2785133 | 0.65 | HRH3 (1.00) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258694-A1 | Amines as histamine-3 receptor ligands and their therapeutic applications | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | claimed |
| US-7538138-B2 | Amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES (US) | 2009-05-26 | — | — | US | claimed |
| US-20050192277-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2005-09-01 | — | — | US | claimed |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-11-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192277-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH2 | HRH3 1/4885DRD2 899/4885DRD1 1552/4885 |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HRH3 1/4885DRD2 999/4885DRD1 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.